SamanthaMalloryMD

Clinical Trials

• Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2019 Jul 08

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator

• Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27

  Recruiting

  Roles: Principal Investigator

• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Start of enrollment: 2020 Oct 13

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator

• Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27

  Recruiting

  Roles: Principal Investigator

• Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) Start of enrollment: 2018 May 14

  Active, not recruiting

  Phase 3

  Roles: Principal Investigator

• Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy Start of enrollment: 2015 Feb 19

  Active, not recruiting

  Not Applicable

  Roles: Principal Investigator

• A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT Start of enrollment: 2020 Oct 19

  Recruiting

  Phase 2

  Roles: Principal Investigator

• Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2020 Jul 20

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator

• Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery Start of enrollment: 2018 May 24

  Active, not recruiting

  Phase 2, Phase 3

  Roles: Principal Investigator

• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2018 Apr 17

  Recruiting

  Phase 2

  Roles: Principal Investigator

• A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2020 Dec 04

  Suspended

  Phase 2

  Roles: Principal Investigator

• A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma Start of enrollment: 2020 Jan 15

  Recruiting

  Phase 3

  Roles: Principal Investigator

• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Start of enrollment: 2017 Aug 23

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator

• Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma Start of enrollment: 2014 Aug 08

  Active, not recruiting

  Phase 3

  Roles: Principal Investigator

• Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia Start of enrollment: 2020 Apr 06

  Active, not recruiting

  Phase 1, Phase 2

  Roles: Contact, Principal Investigator

• A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma Start of enrollment: 2020 Jan 31

  Recruiting

  Phase 3

  Roles: Principal Investigator

• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Start of enrollment: 2021 May 03

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator

• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Start of enrollment: 2017 Jul 31

  Recruiting

  Phase 2

  Roles: Principal Investigator

• Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma Start of enrollment: 2017 Nov 17

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator

• Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Start of enrollment: 2017 Aug 08

  Recruiting

  Phase 3

  Roles: Principal Investigator

• Project: Every Child for Younger Patients With Cancer Start of enrollment: 2015 Nov 03

  Recruiting

  Roles: Principal Investigator

• Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Start of enrollment: 2017 Nov 28

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator

• Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Start of enrollment: 2017 May 25

  Recruiting

  Phase 3

  Roles: Principal Investigator

• A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Start of enrollment: 2020 Jul 21

  Active, not recruiting

  Phase 3

  Roles: Principal Investigator

• Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors Start of enrollment: 2017 Dec 06

  Active, not recruiting

  Roles: Principal Investigator

• A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Start of enrollment: 2019 Jul 03

  Recruiting

  Phase 3

  Roles: Principal Investigator

• Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study Start of enrollment: 2020 Dec 07

  Active, not recruiting

  Phase 3

  Roles: Principal Investigator

• Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Start of enrollment: 2019 Oct 31

  Recruiting

  Phase 3

  Roles: Principal Investigator

• Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia Start of enrollment: 2019 Nov 08

  Recruiting

  Phase 2

  Roles: Principal Investigator

• A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma Start of enrollment: 2021 Sep 14

  Recruiting

  Phase 3

  Roles: Principal Investigator

• Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States Start of enrollment: 2022 Mar 14

  Suspended

  Roles: Principal Investigator

• A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT Start of enrollment: 2021 Jul 13

  Recruiting

  Phase 2

  Roles: Principal Investigator

• Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia Start of enrollment: 2017 Jun 19

  Recruiting

  Phase 2

  Roles: Principal Investigator

• Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma Start of enrollment: 2022 Apr 01

  Recruiting

  Phase 3

  Roles: Principal Investigator

• Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Start of enrollment: 2021 Oct 05

  Recruiting

  Phase 3

  Roles: Principal Investigator

• A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for Primary Central Nervous System Tumors Start of enrollment: 2022 May 10

  Recruiting

  Phase 3

  Roles: Principal Investigator

• Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma Start of enrollment: 2022 Aug 04

  Recruiting

  Phase 3

  Roles: Principal Investigator

• A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab Start of enrollment: 2023 May 11

  Recruiting

  Phase 3

  Roles: Principal Investigator

• The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study Start of enrollment: 2022 Apr 18

  Recruiting

  Phase 1, Phase 2

  Roles: Principal Investigator

• Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma Start of enrollment: 2023 Aug 24

  Recruiting

  Phase 3

  Roles: Principal Investigator

• A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) Start of enrollment: 2022 May 31

  Recruiting

  Phase 1, Phase 2

  Roles: Principal Investigator

• Join now to see all